Altered Acylcarnitine Metabolism in cardiac diseases: From molecular mechanisms to translational potential
IJC Heart & Vasculature · 2026-12 · 67 · 102010
DOI: 10.1016/j.ijcha.2026.102010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift IJC Heart & Vasculature, 2026-12. Verfasst von Jiazhen Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical school, Kunming University of Science and Technology, Kunming, 650500, P.R. China. Die Arbeit nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kunming University of Science and Technology.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) are a leading global cause of mortality and disease burden, closely associated with the remodeling of myocardial energy metabolism. Acylcarnitines (Acs) are key intermediates in the carnitine shuttle and fatty acid β-oxidation (FAO) processes. They play a critical role in transporting long-chain fatty acids across the mitochondrial membrane, maintaining the intracellular acyl-CoA/CoA balance, and buffering metabolic flux. Recent metabolomics studies have demonstrated significant abnormalities in acylcarnitine profiles across various cardiac diseases, including coronary artery disease, ischemia-reperfusion injury, heart failure, diabetic cardiomyopathy, and arrhythmias. These abnormalities are closely correlated with disease severity, metabolic disturbances, and poor clinical prognosis. Mechanistically, the pathological accumulation of long-chain acylcarnitines triggers lipotoxicity, exacerbates mitochondrial oxidative stress, and impairs calcium homeostasis, which collectively drive inflammation and cardiomyocyte apoptosis. This review systematically summarizes the physiological roles of the carnitine shuttle, explores the underlying mechanisms of acylcarnitine-induced cardiac injury, and highlights their translational potential as promising diagnostic biomarkers and novel therapeutic targets for cardiovascular metabolic interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical school, Kunming University of Science and Technology, Kunming, 650500, P.R. China.
- Kunming Municipal Hospitalof Traditional chinese Medicine, The Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, 650000, China.
- Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Förderung
- Kunming University of Science and Technology
Zitieren
APA
Wu, J., Zhang, Y., Liu, J., Zhao, W., Liu, X., & Dan, J. (2026). Altered Acylcarnitine Metabolism in cardiac diseases: From molecular mechanisms to translational potential. IJC Heart & Vasculature, 67, 102010. https://doi.org/10.1016/j.ijcha.2026.102010
Vancouver
Wu J, Zhang Y, Liu J, Zhao W, Liu X, Dan J. Altered Acylcarnitine Metabolism in cardiac diseases: From molecular mechanisms to translational potential. IJC Heart & Vasculature. 2026;67:102010. doi:10.1016/j.ijcha.2026.102010
BibTeX
@article{Wu2026,
author = {Wu, Jiazhen and Zhang, Yi and Liu, Jiawei and Zhao, Weidie and Liu, Xuesong and Dan, Juhua},
title = {Altered Acylcarnitine Metabolism in cardiac diseases: From molecular mechanisms to translational potential},
journal = {IJC Heart & Vasculature},
year = {2026},
volume = {67},
pages = {102010},
doi = {10.1016/j.ijcha.2026.102010}
}
EUVIMED